Astatine is the rarest naturally occurring element on Earth and one of the least studied within the periodic table, mostly because it lives up to its name, which is the Greek word for "unstable." ...

Naya Therapeutics Inc. is expanding its hepatocellular carcinoma pipeline with the addition of NY-700, a first-in-class GPC3-targeted Astatine-211 (211At) α radioimmunotherapy aiming to address ...

A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, ...

Astatine‑211 is increasingly recognized as the alpha emitter of choice for targeted radiotherapeutics. Its pure alpha emission results in high‑energy, short‑range cytotoxicity that selectively ...

A team at Texas A&M University has developed an automated system for separating and shipping At-211. This patent-pending device enables the radioisotope to be purified and loaded as part of the ...

Reston, VA (December 4, 2025)--A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a ...